November 16, 2015
Allergan’s Bimatoprost lowers intraocular pressure in glaucoma patients (Phase I/II trial)
A single dose of Bimatoprost Sustained-Release (SR) lowered intraocular pressure (IOP) in 92 percent (n= 69) of glaucoma patients at 4 months and 71 percent (n=53) at 6 months while demonstrating a favorable efficacy and safety profile.